7 July 2022 in Arquivos Brasileiros de Cardiologia
Sumário 1. Epidemiologia 149 2. Definição e Etiologia 150 […] Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022 Sumário 1. Epidemiologia 149 2. Definição e Etiologia 150 […] Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022
1 January 2024 in Arquivos Brasileiros de Cardiologia
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis
1 January 2024 in Arquivos Brasileiros de Cardiologia
1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da [...] 1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da
19 September 2023 in ABC Heart Failure & Cardiomyopathy
Introduction Takotsubo Cardiomyopathy (CT), also known as stress-induced cardiomyopathy, is a reversible syndrome that usually presents as an acute coronary syndrome, especially in postmenopausal women. The pathophysiology involves multiple factors, including coronary vasospasm, microcirculation dysfunction, catecholaminergic aggression, and sympathetic hyperactivity. The diagnosis of the classic presentation is the presence of a segmental alteration in the form of ballooning or dyskinesia in the antero-septo-apical region of the left ventricle, associated with hyperdynamia of the basal segments, in the absence of obstructive [...] Introduction Takotsubo Cardiomyopathy (CT), also known as stress-induced cardiomyopathy, is a reversible syndrome that usually presents as an acute coronary syndrome, especially in postmenopausal women. The pathophysiology involves multiple factors, including coronary vasospasm, microcirculation dysfunction, catecholaminergic aggression, and sympathetic hyperactivity. The diagnosis of the classic presentation is the presence of a segmental alteration in the form of ballooning or dyskinesia in the antero-septo-apical region of the left ventricle, associated with hyperdynamia of the basal segments, in the absence of obstructive
7 October 2026 in Arquivos Brasileiros de Cardiologia
Sumário […] Diretriz Brasileira de Valvopatias – 2026 Sumário […] Diretriz Brasileira de Valvopatias – 2026
10 December 2021 in ABC Heart Failure & Cardiomyopathy
In cardiac amyloidosis, amyloid infiltrate at the atrial level promotes atrial dilation and contractile dysfunction as well as a higher prevalence of atrial fibrillation which, when associated with ventricular diastolic and systolic dysfunction, favors blood stasis and the consequent development of intracardiac thrombosis (ICT) and cardioembolic events. In a study of 116 autopsies of patients with cardiac amyloidosis, conducted at the Mayo Clinic, the presence of ICT was demonstrated in 33% of hearts, with a significantly higher prevalence in patients [...] In cardiac amyloidosis, amyloid infiltrate at the atrial level promotes atrial dilation and contractile dysfunction as well as a higher prevalence of atrial fibrillation which, when associated with ventricular diastolic and systolic dysfunction, favors blood stasis and the consequent development of intracardiac thrombosis (ICT) and cardioembolic events. In a study of 116 autopsies of patients with cardiac amyloidosis, conducted at the Mayo Clinic, the presence of ICT was demonstrated in 33% of hearts, with a significantly higher prevalence in patients